Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smita Joshi

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
The Lancet. HIV|November 30, 2025
Age-specific distribution of cervical precancer and cancer among women living with HIV across seven countries: a systematic review and an individual patient data meta-analysisShona Dalal, Karin Sundström, Ronaldo Silva, et al.
The Lancet. Oncology|November 10, 2023
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trialHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Platelets|November 7, 2023
Deep learning, 3D ultrastructural analysis reveals quantitative differences in platelet and organelle packing in COVID-19/SARSCoV2 patient-derived plateletsSagar S Matharu, Cassidy S Nordmann, Kurtis R Ottman, et al.
Dermatology Research and Practice|October 16, 2025
NEXTODERM: Consensus on Dermatophytosis Diagnosis and Management in NepalSudha Agrawal, N K Singh, Saraswoti Neupane, et al.
Eclinicalmedicine|July 9, 2020
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative studyNicolas Folschweiller, Julio Teixeira, Smita Joshi, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccinationSylla G Malvi, Pulikkottil O Esmy, Richard Muwonge, et al.
JCO Precision Oncology|April 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal AdenocarcinomaSamuel L Cytryn, Raktim Borpatragohain, Karmelina Charalambous, et al.
Human Vaccines & Immunotherapeutics|December 11, 2023
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccineNeerja Bhatla, Richard Muwonge, Sylla G Malvi, et al.
Plos One|December 29, 2020
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort studyRichard Muwonge, Partha Basu, Tarik Gheit, et al.
The Lancet. Oncology|October 11, 2021
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort studyPartha Basu, Sylla G Malvi, Smita Joshi, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
The Lancet. HIV|November 30, 2025
Age-specific distribution of cervical precancer and cancer among women living with HIV across seven countries: a systematic review and an individual patient data meta-analysisShona Dalal, Karin Sundström, Ronaldo Silva, et al.
The Lancet. Oncology|November 10, 2023
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trialHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Platelets|November 7, 2023
Deep learning, 3D ultrastructural analysis reveals quantitative differences in platelet and organelle packing in COVID-19/SARSCoV2 patient-derived plateletsSagar S Matharu, Cassidy S Nordmann, Kurtis R Ottman, et al.
Dermatology Research and Practice|October 16, 2025
NEXTODERM: Consensus on Dermatophytosis Diagnosis and Management in NepalSudha Agrawal, N K Singh, Saraswoti Neupane, et al.
Eclinicalmedicine|July 9, 2020
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative studyNicolas Folschweiller, Julio Teixeira, Smita Joshi, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccinationSylla G Malvi, Pulikkottil O Esmy, Richard Muwonge, et al.
JCO Precision Oncology|April 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal AdenocarcinomaSamuel L Cytryn, Raktim Borpatragohain, Karmelina Charalambous, et al.
Human Vaccines & Immunotherapeutics|December 11, 2023
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccineNeerja Bhatla, Richard Muwonge, Sylla G Malvi, et al.
Plos One|December 29, 2020
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort studyRichard Muwonge, Partha Basu, Tarik Gheit, et al.
The Lancet. Oncology|October 11, 2021
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort studyPartha Basu, Sylla G Malvi, Smita Joshi, et al.
Pageof 7